Overview of Closerin

What is Closerin? An Overview of Cycloserine

Property	Description
Active ingredient	D-cycloserine
Form	Oral Capsule
Pharmacological class	Antibiotic; Second-line Antitubercular Agent
General purpose	Reserved for drug-resistant bacterial infections
Origin	Naturally-derived; commonly synthetic

What Type of Medicine is Closerin (Cycloserine)?

Closerin is the brand name for the active drug D-cycloserine, an antibiotic classified as a second-line antitubercular agent. This medicine is primarily reserved for fighting severe bacterial infections, particularly those caused by Multidrug-Resistant Tuberculosis (MDR-TB) strains that have developed resistance to standard, first-line treatments.

Its chemical structure is similar to the amino acid D-alanine, which leads to its classification as a D-alanine analogue. It was originally derived from the bacterium Streptomyces, but is now commonly produced synthetically. Cycloserine is categorized as a crucial medicine for patients when initial, less toxic treatments are ineffective, reflecting its role in global health efforts.

Composition and Physical Form

Closerin is a single-drug product supplied as an oral capsule designed to be swallowed and absorbed through the digestive system. Each capsule contains the sole active ingredient, D-cycloserine.

This formulation is distinct in that it is administered via the oral route, differentiating it from some other second-line treatments that may require injection. The capsule form is designed for management at home compared to intravenous administration.

What Makes This Antibiotic Different?

Closerin’s unique value is its specific action against bacteria that have already developed strong resistance to common antibiotics. While many antibiotics focus on later steps of bacterial cell wall construction, D-cycloserine works by disrupting key, earlier enzymes needed to build the cell wall's foundation. This distinctive approach is utilized in clinical practice, as the drug's efficacy is often maintained against strains that have developed extensive resistance to most other agents. Its purpose is to act as a fallback option when first-line therapies fail.

Regulatory References

What side effects are possible with Closerin?

Possible Side Effects and Safety Information

The safety profile of Closerin (cycloserine) is largely defined by its effects on the Nervous System and Psychiatric function, which represent the most frequent and most important adverse reactions documented in regulatory sources.

Adverse Reaction Classifications

Side effects are primarily categorized by the System-Organ Class (SOC) they affect, with the central nervous system (CNS) being the primary focus. Officially documented effects include drowsiness, headache, tremor, vertigo, and psychiatric manifestations such as confusion, disorientation, depression, and psychoses.

System-Organ Class	Examples of Documented Adverse Reactions
Nervous System	Convulsions, Somnolence, Dysarthria, Paresthesia, Coma
Psychiatric Disorders	Depression, Confusion, Psychoses (with suicidal tendencies), Aggression, Character change
Vascular / Cardiac	Sudden development of Congestive heart failure

Serious Safety Risks and Contextual Patterns

Official labeling highlights the potential for psychosis with suicidal tendencies and convulsions as serious adverse reactions that require close observation. Toxicity is generally classified as dose-related, meaning that adverse CNS reactions are more likely when blood levels are elevated, such as when the dosage exceeds 500 mg per day. These dose-related effects may appear relatively early in treatment.

Safety Constraints and Special Populations

Regulatory documents establish several contraindications that prohibit the use of Closerin, including pre-existing conditions such as epilepsy or other seizure disorders, existing psychiatric disease (like severe anxiety or psychosis), and severe renal insufficiency. Because the drug passes into breast milk, official labeling notes the potential for serious adverse reactions in nursing infants. Cautious dose selection is advised for older adults due to the likelihood of decreased renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Closerin defines toxicity based on exposure levels: acute toxicity is documented with ingestion exceeding 1 gram, and chronic toxicity is associated with daily dosages greater than 500 mg. The drug’s toxicity primarily affects the Central Nervous System (CNS).

Documented manifestations range from confusion, paresthesias (numbness/tingling), hyperirritability, and psychosis to life-threatening outcomes. The most severe documented outcomes are CNS depression progressing to convulsions (seizures) and coma. Cases of congestive heart failure have also been reported with high daily doses.

Required Emergency Actions

When an overdose is suspected, seek emergency medical attention immediately. Regulators instruct contacting a certified Regional Poison Control Center for current management guidance. In the absence of a specific chemical antidote, treatment involves supportive measures, including the potential administration of anticonvulsant drugs to control seizures and Pyridoxine (Vitamin B6). Patients with renal impairment are documented to be at higher risk of toxicity due to drug accumulation and must have their drug levels monitored.

Therapeutic Uses of Closerin

What Closerin Treats: Main Uses and Benefits

Closerin is commonly used as a second-line agent for conditions marked by increased physiological stress related to drug-resistant bacterial infections. Its primary role is in managing Multidrug-Resistant Tuberculosis (MDR-TB). It may also be part of symptomatic management for certain conditions presenting with systemic or localized discomfort, such as specific urinary tract infections (UTIs).

The primary benefit is that it helps maintain a sense of stability when symptoms are more noticeable during the management of these challenging conditions, playing a role in addressing symptoms related to systemic imbalance (such as persistent fever and generalized fatigue) and pulmonary manifestations (including chronic cough). It supports a more manageable experience and provides supportive relief when symptoms interfere with routine activities.

“This medicine is relevant for managing symptoms that interfere with daily comfort, particularly when symptoms become more disruptive during flare-ups.”

Quick Fact: Support for Systemic Imbalance Closerin is applied in clinical settings involving heightened systemic burden, helping to manage the symptoms related to physical discomfort, such as fever, fatigue, and night sweats, that are associated with active, drug-resistant tuberculosis.

Eligibility and Restrictions for Use

Closerin (D-cycloserine) is reserved for use in specific populations, primarily patients with drug-resistant tuberculosis or urinary tract infections when standard therapies have failed. Its official regulatory profile establishes clear exclusions and conditional use requirements.

Absolute Contraindications

The medicine must not be used in patients with known hypersensitivity to cycloserine. Closerin is strictly contraindicated in patients with a history of epilepsy, psychosis, severe anxiety, or depression, as well as in individuals with severe renal insufficiency or those with excessive concurrent use of alcohol.

Age and Conditional Use

For pediatric patients, the safety and effectiveness of Closerin have not been established according to regulatory documents. Use in older adults requires caution. During pregnancy, the drug is classified as Category C; it should be used only if the potential benefit justifies the risk to the fetus. Since the drug passes into breast milk, a decision must be made to discontinue nursing or discontinue the drug during lactation. Patients with non-severe renal impairment require careful monitoring and use under caution due to the risk of toxicity.

What should I know about interactions with other medicines?

Interaction Scope and Restrictions

The regulatory profile for Closerin (D-cycloserine) is primarily defined by documented interactions involving the Central Nervous System (CNS) and drug clearance. Excessive concurrent use of alcohol is formally contraindicated due to an officially stated risk of increasing the possibility and severity of epileptic episodes (seizures). No mandatory administration-timing separation requirements are specified in official labels.

Pharmacokinetic and Pharmacodynamic Effects

The official documents classify interactions based on two primary mechanisms: exposure alteration and pharmacodynamic potentiation. The antitubercular agent Isoniazid is documented to increase Closerin’s systemic exposure by a mechanism of decreasing metabolism, which may result in an increased incidence of CNS effects. Closerin inhibits the metabolism of Phenytoin, leading to a stated risk of developing toxic blood levels of Phenytoin. Additionally, co-administration with Ethionamide is reported to potentiate neurotoxic side effects, classified as an additive pharmacodynamic effect.

Population-Specific Interaction Note

A critical population-specific constraint is noted for individuals with severe renal insufficiency. This condition leads to inadequate renal clearance of Closerin, which directly correlates with the potential for excessive blood levels (above 30 mu g/mL) and an increased likelihood of toxicity.

Connection to the Overall Interaction Profile

The regulatory documentation defines this product’s interaction structure by concentrating on substances that converge to increase CNS toxicity or alter systemic exposure. This includes specific antitubercular agents, Phenytoin, and the formally restricted combination with alcohol.

Mechanism of Action

️ Molecular Disruption of Bacterial Cell Wall Synthesis

Closerin exerts its primary action by mimicking the bacterial amino acid D-alanine, allowing it to competitively and irreversibly inhibit two core enzymes, Alanine Racemase (Alr) and D-Alanine:D-Alanine Ligase (Ddl). This molecular interference blocks the formation of the essential peptidoglycan building block, D-alanyl-D-alanine, which is a prerequisite for a stable bacterial cell wall. This targeted failure in the early, cytosolic stage of cell wall assembly directly leads to the collapse of the bacterial structure, a fundamental mechanism resulting in loss of bacterial cell structure.

Modulating Central Nervous System (CNS) Signaling

The molecule possesses a secondary mechanism in the human body, where it readily crosses the blood-brain barrier to modulate the N-methyl-D-aspartate Receptor (NMDA-R). Closerin acts as a partial agonist at the receptor's glycine-binding site, influencing the activity of the brain’s main excitatory system, glutamate. This interaction represents a distinct action within the CNS neurotransmitter pathways, a mechanism resulting in altered glutamatergic signaling.

Mechanistic Constraints and Substrate Competition

The molecule's mechanism is physiologically constrained by competition with its natural biological counterpart, D-alanine. High local concentrations of D-alanine can overwhelm the competitive inhibition of the D-Alanine:D-Alanine Ligase enzyme, which results in reduced enzyme blockade. This phenomenon highlights a key biological limitation where substrate availability directly regulates the molecular action of the drug.

Dosage and Administration Information

How Closerin is Used: Official Administration Guidelines

Closerin (cycloserine) is administered exclusively via the oral route as a 250 mg capsule and must always be used as part of a multi-drug regimen. Its use is defined by strict adherence to dose limits and monitoring requirements over an extended period.

Standard Dosing and Schedule

Population	Initial Adult Dosing	Maintenance Range (Max)	Duration Pattern
Adults	250 mg twice daily, for the first two weeks.	500 mg to 1 g daily in divided doses (Do not exceed 1 g daily)	Long-term use, typically 18 to 24 months.
Pediatrics	15–20 mg/kg/day in divided doses (Max: 1 g daily).	Dosage is determined by the healthcare provider based on weight.	Extended course, part of a multi-drug treatment.

Administration is generally in divided daily doses at 12-hour intervals, though once-daily dosing may be considered if tolerated.

Specific Use Requirements

The following parameters are established for the proper use of this medication:

Dose Adjustment (Titration): The maintenance dose is not fixed; it is titrated based on serum drug levels. Dosage must be adjusted to keep the cycloserine blood concentration below 30 mu g/mL.
Monitoring: Blood levels must be determined at least weekly for patients receiving a daily dose over 500 mg or those with reduced kidney function.
Renal Function: Dose reduction or adjustment is explicitly mandated for patients with impaired kidney function to prevent excessive concentration of the drug.
Administration Timing: The medicine is best taken without food, though it may be taken with orange juice to aid administration.
Missed Dose: If a dose is missed, patients should take it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Closerin

Evidence for Use in Multidrug-Resistant Tuberculosis (MDR-TB)

Closerin was studied for its use as a second-line antibiotic, primarily applied in cases of Multidrug-Resistant Tuberculosis (MDR-TB). The research landscape is characterized by clinical treatment cohort studies and retrospective cohort studies, as the use of traditional randomized controlled trials is less common in this specific clinical context. These studies monitored patient populations—consisting of adults and adolescents—and examined outcomes related to the success or failure of the antibiotic regimen, such as a favorable final treatment outcome.

Research highlights changes measured during the study period, including measurements of sputum culture conversion, which refers to when the presence of the Mycobacterium tuberculosis bacteria is no longer found in a patient's sputum sample. Findings describe patterns observed in these studies, indicating that measurements of sputum culture conversion were reported within the first six months of treatment in the observed groups.

Evidence for Use in Specific Urinary Tract Infections (UTIs)

Closerin was also evaluated for use in specific Urinary Tract Infections (UTIs), an application that is primarily documented in historical regulatory records and early clinical case studies. Current research focuses on laboratory settings, where studies examined the drug's activity against various urinary pathogens. This modern research mainly involves in vitro susceptibility testing, which reports how the bacteria respond to the medicine in a test dish.

The scientific evidence for the use of Closerin in UTIs is limited. The data are still emerging and certainty remains low, largely due to a lack of modern, large-scale clinical trials to fully characterize the medicine's role in current UTI management. Consequently, comparative evidence is lacking, and the available clinical information is mostly based on older records.

Understanding Research Gaps and Uncertainty

Despite its inclusion in global health guidelines, the current evidence landscape for Closerin presents several important gaps. Comparative evidence is lacking for large-scale, head-to-head randomized controlled trials comparing it directly against other contemporary MDR-TB agents. The key limitations include the modest sample sizes used in some of the smaller clinical cohorts, and the persistent challenge of pharmacokinetic variability—the inconsistent way the drug is processed by different people. Research highlights that studies contribute to the broader evidence landscape but do not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Closerin (FAQ)

Q: Is Closerin safe for use in older adults?

Official prescribing information indicates that use in older adults requires caution, often due to the increased likelihood of decreased kidney function in this population. When kidney function is impaired, dose adjustment and close monitoring of blood levels are required procedures to prevent excessive concentration of the drug.

Q: Can women who are planning pregnancy use Closerin?

Closerin is classified as Pregnancy Category C. Official information advises patients who are pregnant or are planning to become pregnant to inform their healthcare provider. The decision involves a healthcare provider assessing whether the potential benefit of the drug justifies the potential risk to the fetus.

Q: Why do some people say Closerin didn't work for them?

Studies suggest that the drug’s molecular effect can be physiologically limited by competition with a natural substance in the body called D-alanine, which may reduce its intended action. Researchers have also noted challenges related to the medicine’s penetration into lung cavities in some patients.

Q: How is Closerin different from the generic version, if one exists?

Closerin is the brand name for the active ingredient D-cycloserine. This active ingredient is also available in generic form. According to regulatory documents, both the brand-name product and the generic version contain the same active medicinal component.

Q: Can Closerin be used by teenagers?

According to official regulatory documents, the safety and effectiveness of Closerin in pediatric patients, including teenagers, have not been established.

Q: Is it possible to be allergic to Closerin?

Yes, the medicine is contraindicated, meaning it should not be used, in patients with a known hypersensitivity to cycloserine or any of its ingredients. The regulatory list of adverse reactions also includes reports of allergic reactions, such as skin rash.

Q: Can I drive while taking Closerin?

Because this medicine can cause side effects such as drowsiness, vertigo, and confusion, it may affect alertness and coordination. Official patient information indicates that, due to potential effects on alertness and coordination, activities like driving or operating machinery should be avoided until the individual's reaction to the medicine is understood.

Q: How quickly does Closerin usually start to have an effect?

The medicine is readily absorbed after it is taken orally. According to pharmacology data, peak concentrations of the drug in the blood typically occur within 4 to 8 hours after an oral dose.

Q: Do I need a special diet while taking Closerin?

Official information specifically recommends against taking the drug with or immediately following a high-fat meal. This is because consuming a high-fat meal may slow down the rate at which the medicine is absorbed by the body.

Q: What happens if I stop taking Closerin suddenly?

Regulatory documents emphasize the importance of completing the full prescribed course of treatment. Finishing the entire course is necessary to reduce the risk of the infection becoming drug-resistant to Closerin or similar medicines.

Q: Can the drug cause weight changes?

Although not a primary listed effect, the regulatory adverse reaction list includes the sudden development of congestive heart failure. Symptoms of heart failure may include swelling or a rapid, unexpected weight gain.

Q: Can Closerin cause problems with vision?

Yes, serious eye symptoms have been reported in official documents. These include sudden vision loss, blurred vision, tunnel vision, or seeing halos around lights.

Q: How long does Closerin stay in the body after the last dose?

The time it takes for half of the drug to be eliminated from the body, known as the half-life, is approximately 10 to 12 hours. This elimination time is based on patients having normal kidney function.

Q: Are there specific vitamins or herbal products that should be avoided with Closerin?

While specific interactions are not widely documented for individual vitamins or herbs, co-administration with other anti-tuberculosis drugs has been associated with deficiencies of Vitamin B12 and/or folic acid. Official labeling suggests patients provide their healthcare provider with a complete list of all vitamins and herbal supplements they are using.

Q: Is Closerin used to prevent a condition or to treat active symptoms?

According to the official Indications and Usage section, the medicine is used for the treatment of active pulmonary and extrapulmonary tuberculosis. It is also indicated for the treatment of acute urinary tract infections.

Q: What happens if I accidentally take two doses close together?

Toxicity from the drug is closely linked to excessive blood levels, specifically above 30 mu g/mL. Taking two doses close together can increase the possibility and risk of CNS symptoms, such as seizures, confusion, or psychosis.

Q: Does having a history of liver issues mean I can't take Closerin?

A history of liver problems is not listed as an absolute contraindication. However, the official label requires caution for patients with a history of impaired hepatic (liver) function. Elevated serum transaminase (a sign of liver stress) has been noted, especially in patients with pre-existing liver disease.

Q: Is the research on Closerin still ongoing?

Yes, research using D-cycloserine is active and ongoing. This includes studies aimed at optimizing dosing for tuberculosis treatment and investigating its potential use in neuropsychiatric applications.

Q: What should I do if a side effect seems to be getting worse?

The official label indicates that symptoms of severe Central Nervous System (CNS) toxicity—such as convulsions, psychosis, or confusion—are conditions that historically prompted discontinuation or dosage reduction. The same action is indicated if the patient develops allergic dermatitis.

How should Closerin be stored and disposed of?

How to Store and Dispose of Closerin

The storage and disposal of Closerin (cycloserine) capsules must adhere strictly to official regulatory guidelines to maintain product quality and ensure safety.

Storage Requirements

Closerin must be stored below 25 C (77 F) and kept out of the sight and reach of children. It is essential to store the medicine in its original container and keep it tightly closed to protect from moisture, which is critical for stability. The product must also be kept from freezing.

Disposal Instructions

Any unused or expired medicinal product or waste material must be disposed of in accordance with local requirements. The labeling directs against discarding medicines via wastewater or household waste, emphasizing that the product should be handled through appropriate pharmaceutical waste protocols.

Closerin